anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Research based on observation has demonstrated a relationship between sleep traits and frailty; however, it remains uncertain if this correlation indicates causation. The purpose of this study was to look at the causal relationship that exists between frailty and sleep traits.
METHOD: Using summaries from a genome-wide association study of self-reported sleep features and frailty index, we performed a bidirectional Mendelian randomization (MR) analysis. Examining the causal relationships between seven sleep-related traits and frailty was the goal. The major method used to calculate effect estimates was the inverse-variance weighted method, supplemented by the weighted median and MR-Egger approaches. The study investigated pleiotropy and heterogeneity using several methodologies, such as the MR-Egger intercept, the MR-PRESSO approach, and the Cochran's Q test. We took multivariate Mendelian randomization and genetic correlations between related traits to enhance the confidence of the results. Furthermore, we used MRlap to correct for any estimation bias due to sample overlap.
RESULTS: Insomnia, napping during the day, and sleep apnea syndrome exhibited a positive connection with the frailty index in forward MR analysis. Conversely, there is a negative link between getting up in the morning, snoring and sleep duration with the frailty index. During the reverse MR analysis, the frailty index exhibited a positive correlation with insomnia, napping during the day, and sleep apnea syndrome, while demonstrating a negative correlation with sleep duration. There was no direct correlation between snoring, chronotype, and frailty. In MVMR analyses, the causal effect of sleep characteristics on frailty indices remained consistent after adjusting for potential confounders including BMI, smoking, and triglycerides.
CONCLUSION: The findings of our investigation yield novel evidence that substantiates the notion of a bidirectional causal connection between sleep traits and frailty. Through the optimization of sleep, it is potentially feasible to hinder, postpone, or even reverse the state of frailty, and we proposed relevant interventions.
Systems and methods used to perform non-contact patient registration of images for surgical navigation are disclosed. In some embodiments, the systems include a 3-D scanning device to capture spatial data of a region of interest of a patient and a reference frame. A digital mesh model is generated from the spatial data. A reference frame model is registered with the digital mesh model. Anatomical features of the digital mesh model and a patient registration model are utilized to register the digital mesh model with the patient registration model. A position of a surgical instrument is tracked relative to the reference frame and the patient registration model.
HMBD-002 administered as a 60-minute IV infusion as a monotherapy. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.
The safety and effectiveness of cabazitaxel in pediatric patients have not been established.

Cabazitaxel was evaluated in 39 pediatric patients (ages 3 to 18 years) receiving prophylactic G-CSF. The maximum tolerated dose (MTD) was 30 mg/m 2 intravenously over 1 hour on Day 1 of a 21 day cycle in pediatric patients with solid tumors based on the dose-limiting toxicity (DLT) of febrile neutropenia. No objective responses were observed in 11 patients with refractory high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). One patient had a partial response among the 9 patients with ependymoma. 

Infusion related/hypersensitivity reactions were seen in 10 patients (26%). Three patients experienced serious adverse events of anaphylactic reaction. The incidence of infusion related/hypersensitivity reactions decreased with steroid pre-medication. The most frequent treatment-emergent adverse events were similar to those reported in adults.

Based on the population pharmacokinetics analysis conducted with data from 31 pediatric patients with cancer (ages 3 to 18 years), the clearances by body surface area were comparable to those in adults.
In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
The present invention relates to a triple hybrid vector amplicon system comprising genetic elements derived from Herpes Simplex Virus (HSV), Epstein-Barr Virus (EBV) or Adeno-Associated Virus (AAV), and a retrovirus. The vector was developed to stably transform cells, both in culture or in vivo, into retrovirus packaging cells in a single step. This step can be accomplished both by transfection using liposomes, electroporation, calcium phosphate, or any other methodology used to transfer naked or complexed DNA into cells or by infection when the vector is packaged as an amplicon vector in HSV virions. In one embodiment, the system takes advantage of the host range and retention properties of HSV/EBV hybrid amplicons to efficiently convert cells to retrovirus vector producer cells after single-step transduction. Retrovirus genes gag-pol and env (GPE) and retroviral vector sequences were modified to minimize sequence overlap and cloned into an HSV/EBV hybrid amplicon. In a second embodiment, retrovirus gag-pol and env genes and a retrovirus vector carrying lacZ, were cloned into HSV/AAV hybrid amplicons. These hybrid amplicon vector systems hold great potential for the generation of new retrovirus packaging lines derived from cells that due to their migratory, tumor or tissue targeting properties, can expand the spatial distribution of gene delivery by retrovirus vectors in vivo.
The present invention relates to a new composition comprising gas-filled microvesicles for contrast imaging which are particularly suitable for providing an effective echo response to at least two selected ultrasound waves having different frequencies. Said composition preferably comprises at least two different preparations of gas-filled microvesicles, which preferably have respective different mean sizes. In particular, said preparations preferably have respective D v  values differing from each other by at least 0.5 μm, more preferably at least 1.0 μm. Alternatively, said composition has a volume size distribution showing a value of Bowley skewness of 0.16 or higher. According to a preferred embodiment, at least 95% of the total volume of gas contained in said microvesicles, calculated on the population of microvesicles up to a diameter of 10 μm, is contained in microvesicles having a diameter of 8 micron or less. The composition of the invention can be effectively employed at rather different ultrasound transmission frequencies differing by about 8 MHz.
FIELD: medicine, particularly, pharmaceutical production. SUBSTANCE: invention deals with preparing a new medicinal agent in the form of suppository on base of bigluconate chlorhexine. The agent may have a wide application for treatment of urogenital pathology of women and prophylaxis of venereal diseases, such as syphilis, gonorrhea and trichomonosis. The new treatment-and-prophylactic preparation "Geksikon" on base of bigluconate chorhexine is made in the form of suppository and additionally contains a bade at the following ratio of components, g per one suppository: bigluconate chlorhexine, 0.014-0.018; base, the balance. As a base it contains hydrophilic one, preferably, polyethyleneoxide base. Preferably used in polyethyleneoxide base is polyethyleneoxide with maximum molecular moisture- absorbing capacity 1500 in the amount of 92-98% and polyzhethyleneoxide with maximum molecular moisture-absorbing capacity 400 in the amount of 2-8%. Hydrophilic base is used in the amount sufficient for preparation of a suppository with mass of 2.90-3.25 g. Bigluconate chlorhexine is preferably used as 20-% aqueous solution. The proposed preparation is well endured by patients, nontoxic and does not cause allergy and side effects. EFFECT: higher antiseptic and antibacterial action; higher efficiency for treatment and prophylaxis of venereal diseases. 4 cl, 1 tbl, 4 ex
Compositions and methods are provided for the prevention or treatment of RSV infection and SARS-CoV2 virus related infections, such as COVID-19 (2019-nCoV), in a human. The methods include administering one or more doses of a composition comprising an encapsulated nano-metal oxide (NMO) or nano-metal oxide chelate (NMO-Ch). The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets. Particles or droplets contain material systems that include composite particles having a core and one or more shells that enclose the core. In this case, the shell is a nonlamellar amorphous material, and the internal matrix core contains a metal oxide or metal oxide chelate.
PURPOSE: A pharmaceutical composition containing Acanthopanax sessiliflorum seeman fruit extract, fraction, compound isolated from the same, or pharmaceutically acceptable salt thereof is provided to prevent and treat cancer with reduced side effect. CONSTITUTION: A pharmaceutical comosition for preventing and treating cancer contains Acanthopanax sessiliflorum seeman fruit extract as an active ingredient. The extract is methanol extract prepared by dipping Acanthopanax sessiliflorum seeman fruits in 70% ethanol, filtering, and concentrating by reduced pressure. The pharmaceutical composition contains Acanthopanax sessiliflorum seeman fruit fraction as an active ingredient. The fraction is prepared by fractioning the extract with ethyl acetate and n-butanol. The pharmaceutical composition contains compounds isolated from the fraction or pharmaceutically acceptable salt thereof as an active ingredient. The compound x is acanthosessilioside A of chemcial formula 1, acanthosessilioside I of chemical formula 2, or methyl acanthosessiligenin of chemical formula 3.
Right ventricular (RV) dysfunction is mostly associated to a decrease in contractility, right ventricular pressure overload or right ventricular volume overload. RV dysfunction can occur in a number of clinical scenarios in the intensive care unit (ICU) and operating room (OR): pulmonary embolism, acute respiratory distress syndrome (ARDS), septic shock, RV infarction, and in pulmonary hypertensive patients undergoing cardiac surgery.

Unfortunately, identifying which patients will develop RV dysfunction and then progress towards RV failure have proven difficult. One of the reasons for delaying the diagnosis of RV dysfunction could be the lack of uniform definition, especially in the perioperative period. Echocardiographic definitions of RV dysfunction have been described: RV fractional area change (RVFAC) \< 35 %, tricuspid annular plane systolic excursion (TAPSE) \< 16 mm, tissue Doppler S wave velocity \<10 cm/s, RV ejection fraction (RVEF) \<45% and RV dilation. However, echocardiographic indices alone are insufficient in describing RV function. The diagnosis of fulminant RV failure is more easily recognised as a combination of echocardiographic measures, compromised hemodynamic measures and clinical presentation. RV dysfunction is inevitably associated with absolute or relative pulmonary hypertension because of the anatomic and physiological connection between the RV and pulmonary vascular system. The gold standard for measuring pulmonary pressure is still the pulmonary artery catheter. However, RV output can initially be preserved despite of pulmonary hypertension. It is therefore mandatory that early, objective, continuous, easily obtainable and subclinical indices of RV dysfunction are found and validated to initiate early treatment of this disease.
PURPOSE:To provide the deodorizer which has the weak smell of the deodorization components themselves, is effectual to various odorous materials and is particularly effective to ammonia, trimethylamine and methyl mercaptan by subjecting the raw or dried leaves or petals of Saxifragaceae plant, more specifically hydrangea plant to extraction by using a polar solvent and using the resulted extract as an effective component. CONSTITUTION:The raw or dried leaves or petals of the Saxifragaceae plant are subjected to the extraction by using the polar solvent. The polar solvent is exemplified by hydrophilic solvents, such as water, lower alcohol and ketones; more preferably the polar solvent is a mixture and the extraction is executed by using, for example, the solvent prepd. by mixing water and ethanol at 1:4. The method for obtaining the deodorizing material is executed by removing moisture from raw materials in an oven set at 60 deg.C to dry the same, then pulverizing the material by using a mixer. The above mentioned solvent is added to this powder and after the extraction is executed for one hour at 60 deg.C, the powder is subjected to the room-temp. extraction. The liquid is filtered and further, the similar solvent is added to the residue. The liquid is separated and filtered after the warm extraction. The filtrate is joined with the previously separated extraction liquid and is subjected to a thickening operation by a rotary evaporator, etc.
Nurses are frontline practitioners in the fight against COVID-19. Empowering nurses through training for infection prevention for COVID-19 is an essential step to facilitate nurse leadership and safety in the hospital. There is immense reliance on nurses with regard to patient safety, yet very little effort is made to invest in interventions for their leadership roles in developing countries, including Pakistan. In this study the aim is to deliver an intervention for COVID-19 preventive protocols to nurses and assess the impact of the intervention through a pre and post-test survey. A total of 200 nurses will be sampled. A 100 nurses each will be part of the control and experiment group each.

The data will be analyzed using SPSS. Pre and post test results will be presented using descriptive data and bivariate regression will be used to present higher odds of confidence in preventive and awareness literacy for COVID-19 in nurses after intervention delivery. Through this research the aim is to improve nurse leadership in maintaining minimum service delivery standards for hospital infection control with respect to COVID-19; but also other infectious disease burden management.
Cachexia is an irreversible condition that involves a significant loss of body weight, muscle mass, and adipose tissue. It is a complex condition that involves a variety of metabolic, hormonal, and immune-related factors, with the precise mechanisms not yet fully understood. In this review, the prevalence of cachexia in different types of cancer as well as the potential risk factors was evaluated from literature retrieved from databases such as ScienceDirect, PubMed and Scopus. Potential risk factors evaluated here include tumor-related factors such as location, and stage of the cancer, as well as patient-related factors such as age, gender, and comorbidities. Several findings were observed where cachexia is more prevalent in male cancer patients than females, with higher incidences of weight loss and poorer outcomes. This may be due to the different muscle compositions between gender. Additionally, cachexia is more prevalent at the later stages, which may be brought about by the late-stage diagnosis of certain cancers. The anatomical location of certain cancers such as the pancreas and stomach may play a significant factor in their high prevalence of cachexia. These are sites of the synthesis of digestive enzymes and hormones regulating appetite. Cachexia is an issue faced by cancer patients which could affect their recovery. However, it is poorly understood, which limit therapeutic options. Hence, understanding this disease from different perspectives (clinical and pre-clinical), and bridging those findings could further improve our comprehension and consequently improve therapeutic options.
INTRODUCTION: This study assesses the impact of dietary modification, specifically sugary snack restriction, in conjunction with a brisk walking program on overweight management in young overweight women, with a focus on changes in body composition and glucose metabolism.
METHOD: An 8-week randomized controlled trial was conducted amidst the COVID-19 pandemic, utilizing a remote intervention approach to comply with health guidelines and ensure participant safety. The study's remote nature highlights adaptability in health interventions during challenging periods, such as the COVID-19 pandemic. Twenty-one overweight Korean women aged 20-39, with an average BMI of 24.6, were selected for the study. They were divided into two groups: one engaging in brisk walking and the other combining this exercise with a sugary snack restriction, demonstrating the study's focus on comparative intervention efficacy.
RESULTS: The exercise-only group showed notable reductions in glucose, insulin, HOMA-IR (p < 0.05), and total cholesterol levels (p < 0.01). In contrast, the group that combined exercise with dietary modification displayed more pronounced improvements in body weight, fat mass, and waist circumference (p < 0.05). This differential outcome emphasizes the added benefit of integrating dietary control with physical activity.
DISCUSSION: The findings suggest that adding a dietary component, particularly a sugary snack restriction, to an exercise regimen can significantly enhance the effectiveness of overweight management in young women. This study underscores the importance of holistic lifestyle interventions that combine dietary and physical activity modifications for improved health outcomes.
Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage. Thereafter, MP-TLT will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations. In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning.
Provided are mechanisms and processes for a more effectively monitoring infants to enhance caregiving and infant development. A system may include a wearable infant monitoring device having multiple sensors, a transmission interface, and a wearable casing. The multiple sensors gather measurement data associated with activity of an infant. The transmission interface transmits the measurement data detected by the multiple of sensors to a remote monitoring hub. A wearable casing is configured to house the plurality of sensors and transmission interface. The wearable casing and the multiple sensors include mechanisms to determine whether the infant is prone or supine.
Metabolic-associated fatty liver disease (MAFLD) encompasses various chronic liver conditions, yet lacks approved drugs. Hypoxia-inducible factor-1α (HIF-1α) is pivotal in MAFLD development. Our prior research highlighted the efficacy of the nano-designed carbon monoxide (CO) donor, targeting HIF-1α in a mouse hepatic steatosis model. Given heme oxygenase-1 (HO-1, a major downstream molecule of HIF-1α) as the primary source of intrinsic CO, we hypothesized that upregulation of HO-1/CO, responsive to HIF-1α, forms a negative feedback loop regulating MAFLD progression. In this study, we explored the potential negative feedback mechanism of CO on HIF-1α and its downstream effects on MAFLD advancement. HIF-1α emerges early in hepatic steatosis induced by a high-fat (HF) diet, triggering increased HO-1 and inflammation. SMA/CORM2 effectively suppresses HIF-1α and steatosis progression when administered within the initial week of HF diet initiation but loses impact later. In adipose tissues, concurrent metabolic dysfunction and inflammation with HIF-1α activation suggest adipose tissue expansion initiates HF-induced steatosis, triggering hypoxia and liver inflammation. Notably, in an in vitro study using mouse hepatocytes treated with fatty acids, downregulating HO-1 intensified HIF-1α induction at moderate fatty acid concentrations. However, this effect diminished at high concentrations. These results suggest the HIF-1α-HO-1-CO axis as a feedback loop under physiological and mild pathological conditions. Excessive HIF-1α upregulation in pathological conditions overwhelms the CO feedback loop. Additional CO application effectively suppresses HIF-1α and disease progression, indicating potential application for MAFLD control.
Disclosed embodiments describe a system and method for identifying, evaluating and routing members of a healthcare benefits system to clinical interventions. The system includes various databases that comprise member claims data and provides the infrastructure to support the integration and exchange of data among representatives of a health benefits plan. It allows for more efficient use of information via the creation and evaluation of a clinical profile that is then used to identify the clinical interventions that may be appropriate for a member. The clinical data is matched to referral thresholds and other eligibility criteria for various clinical and disease management programs to identify appropriate interventions. Member progress in the interventions is tracked to determine whether additional interventions or actions may be needed to further engage the member in health-related activities. Members that do not respond to alerts for interventions may receive further alerts.
Foscarnet is an antiviral compound. Laboratory studies have shown it to be active against HIV. However, only 12 - 22 percent of an oral foscarnet dose is absorbed by the body. Ranitidine suppresses gastric acid output, increasing gastric pH. Thus by increasing gastric pH (decreasing stomach acidity), less foscarnet is expected to be decomposed or broken down in the stomach. Thus, more foscarnet should be absorbed into the body.

Six asymptomatic HIV-infected males, or those with limited symptoms of early AIDS-related complex ( ARC ), will receive one dose intravenously of ranitidine in distilled water and one dose of placebo (distilled water alone), followed in 1 hour by foscarnet in oral solution. The order of ranitidine and placebo is randomized and the two foscarnet doses are separated by at least 72 hours. A nasogastric pH probe is placed on each morning of drug administration to monitor gastric pH.
PURPOSE:An agent for lowering blood sugar, containing a slightly digestible polysaccharide, oligosaccharide, etc. prepared from plants or animals and saccharide consisting of their derivatives as an active ingredient. CONSTITUTION:An agent for lowering blood sugar, containing a saccharide selected from a group consisting of slightly digestible polysaccharides, oligosacchardides and their derivatives (e.g., cellulose, carboxymethyl cellulose, hydroxyethyl starch, mannan, pectic acid, viscous substance of aloe, agar, dammar gum, viscous substance of tamarind seed, etc.). The toxicity of the saccharides is >500mg/kg, extremely low, and can be used in combination with a stabilizer, a preventive or remedy for metabolic diseases or diseases of digestive organs. It can be administered orally, intra-abdominally, or intravenously, but oral administration is preferable. A dose is 0.1-10g/day, especially 0.2-5g/day preferably orally.